Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio's Approved Drugs Database

Faslodex

Fulvestrant

Download PDF containing detailed information. PDF Version

Image Results

Press Releases About Faslodex:
Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report	24th September, 2009	Reportlinker	-- SERMS The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
Hormonal Cancers: Key drivers in a market of change	1st May, 2002	Datamonitor	Hormonal Cancers: Key drivers in a market of change Four major brands, TAP’s Lupron, AstraZeneca’s Zoladex, Nolvadex and
Clinical trials catalyst for market shift	1st January, 1970	Datamonitor	Clinical trials catalyst for market shift London Wednesday July 6 2005 - Worth $4.8 billion in 2004, the cancer*
Cancer therapy: clinical trials to trigger antihormonals market shift	1st January, 1970	Datamonitor	Cancer therapy: clinical trials to trigger antihormonals market shift Despite the decline of some antihormonal therapy classes, opportunities for new growth within the market do exist.

This page has been viewed 23 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Faslodex across BioPortfolio, or for Faslodex Research Reports

Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

BioPortfolio's Approved Drugs Database

Faslodex

Fulvestrant

Image Results

Press Releases About Faslodex: